India: Crunch Time: Compulsory Licensing In India

Last Updated: 15 January 2015
Article by R. Muralidharan and Ashima Katara

Pharmaceutical giant Bayer filed an appeal against the granting of a compulsory licence for Nexavar to Indian generic manufacturer Natco, but in March the IPAB dismissed the appeal, as R. Muralidharan and Ashima Katara report.

In a landmark ruling in one of the world's fastest growing pharmaceutical markets, the Intellectual Property Appellate Board (IPAB) of India upheld the compulsory licence granted to Natco Pharma Limited, an Indian drug manufacturer, for Bayer AG's Nexavar (sorafenib tosylate), an oncology palliative drug.

Natco approached Bayer for a voluntary licence which was refused. Natco then went ahead to file a compulsory licence application before the Controller of Patents on the grounds that the patentee had not worked the patent in India and the drug in question was being imported by the patentee even three years after the grant of patent; that the cost of Bayer's patented drug was Rs280,000 ($5,000) per month and because of the high cost, only about 2 percent of the patients needing the medicines were actually buying it. Natco contended that the requirements of the Indian public were not met in a reasonable way, and that the patented invention was not available to the public at a reasonable cost.

Bayer resisted the grant of the compulsory licence, arguing that an import from other territories is very much 'working of the patent' in India. Bayer argued that it could only sell limited quantities, essentially because the generic competitor had a cheaper substitute which made it difficult for the patentee to get a market for the higher priced product.

Rejecting all Bayer's contentions, the controller granted a compulsory licence to Natco on March 9, 2012. e controller held that Bayer had made the drug available to a small percentage of eligible patients, which did not meet the requirements of the public, that the price of Rs280,000 per month was not "reasonably affordable", and that Bayer's patent was not being "worked" in India as Nexavar was not being manufactured in India. Importation from manufacturing facilities outside India did not satisfy the mandatory requirement of working the patent in India.

The first compulsory licence was granted to Natco on terms that price of the product sold by Natco shall not exceed Rs8,880 ($160) for 120 tablets (one month's requirement). Instead of margin-based royalty as suggested by Natco, the controller fixed a sales-based royalty. Instead of a 2 to 4 percent royalty as provided under the UN procurement norms, the controller ordered 6 percent royalty on net sales, which was based on an ex-factory price minus taxes.

Bayer filed an appeal against the order before the IPAB. On March 4, 2013, the IPAB dismissed the appeal and upheld the compulsory licence granted to Natco.

the IPAB was of the view that the controller was right in holding that the sales of the drug by the appellant at the price of about Rs280,000 was alone relevant for the determination of public requirement and he was also right in considering the purchasing capacity of the public and the evidence available to conclude that the invention was not reasonably affordable to the public.

The IPAB however revised the compulsory licence order to increase the royalty payment to Bayer from 6 percent to 7 percent .

A pertinent aspect in the IPAB decision is the interpretation of the word 'working' under Section 84(1)(c). The controller, while granting the compulsory licence, had held that importation from manufacturing facilities outside India did not satisfy the mandatory requirement of working the patent in India. The IPAB, on the other hand, held that working should be decided on a case- by-case basis and it may be proved that in a given case, the 'working' may be done by way of 'import', but this cannot apply to all cases. The patentee should show why it could not be locally manufactured. A mere statement to that effect is not sufficient and evidence must be shown.

The IPAB also made it clear that the grant of a compulsory licence is not to favour the licensee, but to make the medicine reasonably affordable and accessible to the public. The IPAB further emphasised that these proceedings are neither against the inventor, nor against the compulsory licence applicant, but purely based on public interest.

Patent-price linkage

It seems that the compulsory licence is based on public interest which is in turn related to the price of the drug. This seems to link patents to price control. A similar attempt at 'patent linkage' was made in 2009 when Bayer attempted to link the Patent Act with the Drugs and Cosmetics Act.

Incidentally, the drug product in both cases was the same (sorafenib tosylate). In the patent linkage matter, it was stated that the nodal ministry for the administration of the Drug and Cosmetics Act is the Ministry of Health and Family Welfare whereas for the Patents Act it is the Ministry of Industry and Commerce. The court held against this attempt at bringing in patent linkage.

On similar lines, the price of a drug in India is decided by the National Pharmaceutical Pricing Authority (NPPA) which is under the Department of Pharmaceuticals in the Ministry of Chemicals and Fertilisers. It is a matter of debate whether this could also be considered as patent-price linkage and on how the courts react to it.

A further development relating to compulsory licences is that a committee set up by the Department of Pharmaceuticals to examine the issues of price negotiations for patented drugs, has recently submitted its report. This report mentions that once a government-appointed committee fixes a price for medicines which is accepted by the government, this fixed price would be supposed to be reasonable and therefore it won't be possible for the government to use the tool of compulsory licences on grounds related to the price of the patented medicine.

Bayer is said to have disagreed with the conclusions of the IPAB and is likely to approach the court. The case is set to be a crucial milestone in deciding the fate of pharmaceutical business in India in the wake of price control measures by the government.

Originally published in World Intellectual Property Review Annual, December 2013.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Khurana and Khurana
InvnTree Intellectual Property Services Pvt. Ltd.
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Khurana and Khurana
InvnTree Intellectual Property Services Pvt. Ltd.
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions